Skip to main content
letter
. 2016 May 6;6(5):e418. doi: 10.1038/bcj.2016.27

Table 1. Treatment and outcome of 42 CML patients with myeloid sarcoma.

No. Sex Age MS subgroups Post-MS treatment Response of MSa Response of CMLa F/U timeb (months) Status at last F/U Cause of Death ABL mutations
1 M 72.7 MS1-CP TKI PR SD 20.5 Dead Leukemia PD, MS PD Noc
2 M 47.8 MS1-CP CT+TKI+RT CR SD 26.9 Dead Leukemia PD NT
3 M 50.0 MS1-CP CT+TKI Allo-HSCT CR MMR 27.0 Dead GvHD NT
4 M 52.3 MS1-CP CT+TKI CR CCyR 36.0 Dead Leukemia PD, MS PD T315Ic
5 M 30.3 MS1-CP CT+TKI NA NA 6.2 Alive   NT
6 F 63.5 MS1-CP TKI CR MMR 14.4 Alive   NT
7 M 30.7 MS1-CP TKI CR CCyR 14.3 Alive   NT
8 M 72.8 MS1-CP TKI CR MMR 22.8 Alive   NT
9 M 29.2 MS1-CP CT+TKI CR CMR 22.8 Alive   NT
10 M 52.7 MS1-CP CT+TKI CR MMR 27.8 Alive   NT
11 F 23.3 MS1-CP CT+TKI Allo-HSCT CR CMR 118.8 Alive   NT
12 M 52.7 MS1-CP CT+TKI Allo-HSCT CR CMR 140.9 Alive   NT
13 M 45.3 MS1-CP CT+TKI+RT CR CMR 146.6 Alive   Noc
14 M 36.3 MS2-CPd CT+TKI PD PD 0.8 Dead Leukemia PD, MS PD No
15 M 26.8 MS2-CP CT+TKI PD PD 0.9 Dead Leukemia PD, MS PD NT
16 M 75.1 MS2-CP TKI PR PD 2.1 Dead Leukemia PD NT
17 M 51.0 MS2-CPd CT+TKI+RT PR PD 2.4 Dead Leukemia PD No
18 M 23.2 MS2-CP CT+TKI PR PD 4.2 Dead Leukemia PD, MS PD No
19 M 47.8 MS2-CPd CT+TKI Allo-HSCT CR CCyR 4.9 Dead Leukemia PD T315I
20 M 23.5 MS2-CP CT+TKI CR CHR 6.5 Dead Leukemia PD E255V
21 M 55.5 MS2-CP CT+TKI CR CCyR 7.5 Dead Leukemia PD, MS PD NT
22 F 51.7 MS2-CP CT NA NA 8.3 Dead NA NT
23 M 51.3 MS2-CP CT+TKI PR SD 10.1 Dead Leukemia PD, MS PD NT
24 M 43.1 MS2-CP CT+TKI+RT PR SD 13.9 Dead Leukemia PD E255K
25 M 51.4 MS2-CP TKI+RT CR CCyR 18.4 Dead Leukemia PD, MS PD NT
26 F 48.4 MS2-CPd TKI CR MMR 21.7 Dead Leukemia PD, NT
27 M 57.3 MS2-CP CT+TKI Allo-HSCT CR CMR 88.5 Dead Esophageal cancer No
28 F 39.2 MS2-CP CT+TKI CR CHR 17.8 Alive   NT
29 F 58.4 MS2-CP TKI CR MMR 64.4 Alive   NT
30 M 56.1 MS2-CP TKI CR CMR 126.9 Alive   NT
31 M 19.4 MS2-BP CT+TKI PD PD 0.8 Dead Leukemia PD E255V/K
32 M 82.7 MS2-BP CT+TKI PD PD 2.0 Dead Leukemia PD NT
33 M 45.8 MS2-BP CT+TKI PD PD 0.6 Dead Leukemia PD, MS PD No
34 F 31.9 MS2-BP CT+TKI+RT Allo-HSCT PR CHR 5.2 Dead Leukemia PD No
35 M 53.4 MS2-BP CT+TKI PD PD 7.4 Dead Leukemia PD NT
36 M 53.2 MS2-BP CT+TKI CR PD 8.7 Dead Leukemia PD F317L
37 M 54.3 MS2-BP CT+TKI Allo-HSCT CR CCyR 9.7 Dead Leukemia PD No
38 M 34.9 MS2-BP CT+TKI CR MMR 13.6 Dead Infection E255
39 M 38.4 MS2-BP CT NA NA 15.7 Alive   NT
40 M 22.0 MS2-BP CT NA NA 0.5 Alivee   NT
41 F 59.0 MS2-BP CT NA NA 1.0 Alivee   NT
42 M 44.3 MS2-BP CT+TKI Allo-HSCT CR MMR 28.9 Alive   NT

Abbreviations: age, age at diagnosis of MS; allo-HSCT, allogeneic hematopoietic stem cell transplantation; BP, blast phase; CCyR, complete cytogenetic response; CHR, complete hematologic response; CML, chronic myelogenous leukemia; CP, chronic phase; CR, complete response; CT, chemotherapy; F, female; F/U, follow-up; GvHD, graft-vs-host disease; M, male; MMR, major molecular response; MS, myeloid sarcoma; MS1, MS at initial diagnosis of CML; MS2, MS arising during course of treatment; NA, not applicable; NT, not tested; PD, progressive disease; PR, partial remission; RT, radiation treatment; SD, stable disease; TKI, tyrosine kinase inhibitor. CR of MS was defined as complete disappearance of the lesion(s). PR of MS was defined as decreased size but not complete disappearance of the lesion(s). CHR, CCyR and MMR are defined according to the NCCN and European LeukemiaNet Guidelines.

a

The best initial response of extramedullary and medullary disease after MS emergence.

b

The follow-up time after MS emergence.

c

ABL mutations detected after MS emergence.

d

The patients had a history of CML-BP but reverted to CP status when MS2 developed.

e

Lost F/U after one course of treatment.